Coponent

Quick links to important sections

Coponent

Method of action: Antihypertensive

Treatment option: Hypertension, Angina Pectoris

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coponent

Quick Facts: Coponent (Nicardipine)

Property Description
Active ingredient Nicardipine hydrochloride
Form Capsule (Oral), Solution (Intravenous)
Pharmacological class Calcium Channel Blocker (Dihydropyridine)
General purpose Lowering elevated blood pressure
Origin Synthetic organic compound

1. Coponent: Defining the Drug and Its Composition

Coponent is a brand name for a synthetic, single-ingredient medicine whose primary therapeutic function is provided by the active substance, nicardipine hydrochloride. As a manufactured synthetic organic compound, Nicardipine is meticulously formulated to ensure a high level of consistency and purity.

This medication is prepared for administration in various dosage forms, including an oral formulation—typically a capsule, often available in an extended-release version—and a sterile solution for injection for intravenous (IV) use. This dual availability is clinically recognized for accommodating both long-term oral management and acute intravenous intervention needs.


2. What Type of Medicine is Nicardipine?

Nicardipine is classified as a second-generation agent within the dihydropyridine family of calcium channel blockers (CCBs). This places it in a major class of cardiovascular agents defined by their specific mechanism.

The classification as a calcium channel antagonist means the drug interferes with the influx of calcium ions into specific muscle cells. Nicardipine is structurally designed to primarily act on the arteries, leading to peripheral widening and better blood flow.


3. General Purpose as a Cardiovascular Agent

The overarching purpose of Coponent is to function as a potent vasodilator agent and antihypertensive agent, crucial roles in regulating elevated blood pressure. Its fundamental action involves causing peripheral vasodilatation, which directly reduces the systemic vascular resistance in the body.

By decreasing this circulatory resistance, the heart works against less force, which efficiently achieves the general therapeutic benefit of lowering elevated blood pressure. This mechanism is particularly valued for its recognized utility when swift, precise control over the vascular system is required.

Regulatory References

  1. View MedlinePlus Drug Information

What side effects are possible with Coponent?

Possible Side Effects and Safety Information

The official safety profile for Coponent (Nicardipine) details adverse reactions predominantly linked to its potent vasodilatory action, as documented in government regulatory sources. These effects are classified by the body systems they affect and their documented frequency in clinical studies.

Adverse Reactions and System Classification

Adverse events are often grouped into specific system-organ classes (SOCs) for regulatory clarity. Reactions documented include effects on the Cardiovascular System (e.g., hypotension, tachycardia, flushing, and peripheral edema), the Nervous System (e.g., headache and dizziness), and the Gastrointestinal System (e.g., nausea and vomiting).

Headache, Hypotension, Tachycardia, and Edema are among the most frequently observed effects reported in clinical trials for both the oral and intravenous forms.

Serious Adverse Reactions and Safety Constraints

Specific serious adverse reactions are highlighted in the official prescribing information due to their clinical significance. These include the potential for an Exacerbation of Angina (an increase in the frequency or severity of chest pain) and instances of Symptomatic Hypotension. Use also requires caution in patients with existing heart conditions, such as the potential for Worsened Heart Failure in those with severe left ventricular dysfunction.

Safety limitations exist, including a formal Contraindication for use in individuals with Advanced Aortic Stenosis and known hypersensitivity to the drug. Additionally, the risk of increased angina has been observed upon the initiation of therapy or during dose escalation of the oral formulation.

Population-Specific Safety Notes

Official documents note that patients with Hepatic Impairment or Renal Impairment may require specific monitoring, as altered drug clearance in these groups can lead to higher systemic drug exposure. Older adults are also advised to be closely observed for excessive pharmacological effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Coponent (nicardipine) define the overdose profile primarily by its severe effects on the cardiovascular system, resulting from exposure to excessive doses. This profile necessitates immediate action due to the potential for life-threatening outcomes.

Overdose manifestations are documented to include profound hypotension (dangerously low blood pressure) and marked bradycardia (abnormally slow heart rate), alongside clinical signs of excessive peripheral vasodilation. Central Nervous System involvement is also documented, presenting as drowsiness and confusion.

The regulatory profile classifies the outcomes as potentially severe and life-threatening. Documented critical effects include cardiogenic shock, high-degree atrioventricular (AV) conduction block, coma, and cardiac arrest.

Immediate medical attention is required upon any suspected overdose. Emergency medical services must be contacted immediately for symptoms such as profound hypotension or loss of consciousness, as hospitalisation is mandatory for continuous observation and intensive cardiac monitoring.

Management relies on mandated symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known for nicardipine overdose. Specific procedural steps documented in official labeling include the administration of intravenous calcium, vasopressors (such as dopamine or norepinephrine) to counteract severe hypotension, and atropine for persistent bradycardia. An extended observation period is required due to the potential for delayed haemodynamic instability.

Therapeutic Uses of Coponent

What Coponent Treats: Main Uses and Benefits

The primary role of Nicardipine is within the therapeutic domain of cardiovascular management, where it is generally used for conditions associated with acute or episodic changes in the circulatory system. This medication is commonly applied in addressing two main areas: high blood pressure and angina (chest pain). The medicine is relevant for easing symptoms related to systemic imbalance by helping with blood pressure control, and also helps address symptoms related to physical discomfort linked to organ-specific functional stress.

The medication is commonly used across conditions characterized by periods of heightened symptoms, relevant for both the long-term management of chronic stable high blood pressure and in clinical settings that involve acute or unstable symptom patterns, such as severe hypertensive episodes. It also plays a role in managing angina pectoris, including chronic stable angina and chest pain caused by coronary artery spasms. The core benefit is that it contributes to improved comfort by supporting the patient during difficult episodes and assisting with maintaining functional stability. The approach helps to ease the overall symptom burden when conditions produce significant symptomatic manifestations.

“This medication is applied across therapeutic domains where additional symptomatic support is needed, primarily focusing on supporting stability of vascular pressure and reducing ischemic discomfort.”


Quick Fact: Relief for Vascular and Ischemic Symptoms

Category Role in Symptom Management
Symptomatic Target Elevated blood pressure and ischemic chest pain.
Use Contexts Chronic stable management and acute critical intervention.
Key Patient Benefit Supports comfort and helps maintain functional stability.
Conditions Hypertension, Angina Pectoris, Postoperative Hypertension.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Coponent?

The population eligibility for Coponent (nicardipine) is strictly defined by regulatory authorities based on contraindications and patient-specific conditions. Only adults without specific exclusionary factors are eligible for standard use.


Absolute Prohibitions (Contraindications)

Coponent must not be used in patients with known hypersensitivity to the drug or any excipients. Use is also contraindicated for individuals diagnosed with advanced aortic stenosis, unstable angina, or within eight days following a myocardial infarction. The intravenous formulation is explicitly prohibited in the presence of an acute intracranial haemorrhage or a rupture of a cerebral aneurysm.


Restricted Use Populations

Official labeling mandates caution and close monitoring for certain populations:

  • Organ Impairment: Patients with impaired hepatic function or severe renal impairment require regulated use and often lower initial doses.
  • Age and Life Stage: Safety and efficacy have not been established in the pediatric population (under 18 years). Use in older adults requires initial low doses. The medicine is not recommended during pregnancy or breastfeeding.

What should I know about interactions with other medicines?

The regulatory profile for Coponent (Nicardipine) interactions centers on its impact on drug metabolism and its additive cardiovascular effects. The official interaction map defines constraints and requirements based on these regulatory categories.

Pharmacokinetic Interactions

Nicardipine is a documented inhibitor of multiple Cytochrome P450 enzymes, notably CYP3A4, CYP2D6, CYP2C8, and CYP2C19. This enzyme inhibition causes elevated plasma concentrations of co-administered medicines that are substrates of these enzymes. Specifically, the systemic exposure of immunosuppressants like Cyclosporine and Tacrolimus is increased, a regulatory finding that necessitates professional monitoring. Conversely, co-administration with strong CYP3A4 inhibitors, such as Cimetidine and Grapefruit Juice, causes an increase in Nicardipine’s own plasma concentration.

Pharmacodynamic and Population Constraints

An additive effect on blood pressure and cardiac contractility is documented when Nicardipine is combined with beta-blockers or other antihypertensive agents. The regulatory label lists Advanced Aortic Stenosis as a contraindication for use, and Intravenous Dantrolene is classified as an unadvised combination. Furthermore, patients with impaired hepatic or renal function exhibit slower systemic clearance of Nicardipine, which officially increases the systemic exposure and interaction potential of the medicine.

Mechanism of Action

The mechanism of action for Coponent (nicardipine) is centered on the selective modulation of ion transport, influencing the tone of the arterial network.

Nicardipine's primary action is the blockade of voltage-dependent L-type calcium channels (VDCCs) found predominantly on the surface of vascular smooth muscle cells. By inhibiting the influx of extracellular calcium ions ( Ca^2+), the drug prevents the molecular signaling necessary to initiate muscle contraction, which is the foundational step of its mechanism.

This molecular blockade initiates a cascade leading to the relaxation of arterial smooth muscle (vasodilation) throughout the systemic and coronary circulations. This widespread effect causes a reduction in Systemic Vascular Resistance (SVR), which is the total opposition to blood flow, thereby establishing the primary physiological consequence of the drug's activity.

The drug demonstrates a high degree of vascular selectivity, concentrating its action on blood vessels with minimal direct effect on the heart's rate or contractility. This selectivity is a key characteristic of its mechanistic action, though it introduces a constraint where a rapid pressure drop can trigger the baroreceptor reflex, a compensatory action that may increase heart rate.

Dosage and Administration Information

Coponent (nicardipine) is officially utilized through two primary routes of administration: oral capsules and a solution for intravenous (IV) continuous infusion. The oral formulations include both Immediate-Release capsules, available in strengths such as 20 mg and 30 mg, and Sustained-Release capsules, available in strengths up to 60 mg.

Oral administration requires divided daily dosing. The Immediate-Release form is typically scheduled three times a day (TID), with an initial dose often starting at 20 mg. The Sustained-Release form is administered twice a day (BID), starting from 30 mg per dose. Dose adjustments for the oral formulations must occur at intervals of at least three days to allow for plasma concentration steady-state achievement.

The IV solution is designated for short-term treatment and must be administered by slow continuous infusion, not as a bolus. Administration starts at an initial rate of 5 mg/hour, which can be titrated in 2.5 mg/hour increments every 5 to 15 minutes up to a maximum rate of 15 mg/hour. The single-dose solution often requires dilution before infusion and must be managed using an electronic syringe driver in a monitored setting. Special instructions include initiating therapy in older adults at the low end of the adult dosing range. Furthermore, the transition from continuous IV infusion to the oral capsule requires the first oral dose to be administered one hour prior to discontinuing the intravenous flow. If an oral dose is missed, the instruction is to skip the missed dose if it is near the next scheduled time and not to take a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Post-Herpetic Neuralgia (PHN)

Research included studies focusing on post-herpetic neuralgia (PHN). This condition involves persistent nerve pain following a shingles episode. Clinical investigation has included its use in chronic neuropathic pain populations.

The primary studies reported an evaluation of changes in patient-reported pain scales (e.g., VAS and NPS scores). These trials focused on patients who experienced pain relief with standard analgesic treatments, but had residual or breakthrough pain. Pre-clinical studies and hypotheses have explored the mechanism of action related to specific pain pathways, with studies also including assessments of time-based patient responses.

Diabetic Neuropathy

The largest body of evidence relates to Type II diabetes-associated neuropathic pain. Key studies investigated changes in reported pain severity and frequency for patients with Type II diabetes.

  • Randomized Controlled Trials (RCTs): Multiple RCTs compared the study drug to placebo and other active comparators. These trials focused primarily on patients with moderate-to-severe pain that persisted despite optimized blood glucose management. The primary endpoints in these trials involved measurement of the 24-hour average pain score from baseline.
  • Long-term Data Collection: Research includes a number of open-label extension studies that have collected data on participants for up to one year.

Other Pain Syndromes

Some studies have investigated the use in other chronic pain conditions, including fibromyalgia and spinal cord injury-related neuropathic pain.

Studies included secondary measurements of patient-reported sleep quality.

Research has included analysis of data regarding initial dosage levels and reported occurrences of side effects. While findings were reported as mixed, the current body of research continues to investigate its applicability in the context of pain. Trial data also included reported quality of life metrics.

Key Studies & References

  1. Efficacy and Safety of Coponent in Post-Herpetic Neuralgia: A Phase 3 Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Coponent (FAQ)


Q: How long does it usually take to feel the effects of Coponent?

Official prescribing information indicates that following an oral dose, the drug's active substance becomes detectable in the bloodstream as early as 20 minutes. The maximum concentration in the blood, which correlates with the potential peak effect, is typically reached between 30 minutes and 2 hours after administration.


Q: What are the most common reasons someone would stop taking Coponent?

Official safety summaries indicate that the most frequently observed effects in clinical studies are related to the drug's widening of blood vessels. Common adverse reactions include headache, hypotension (low blood pressure), tachycardia (fast heart rate), and edema (swelling). These common effects are often cited as the primary reasons why individuals discontinue treatment.


Q: Can Coponent affect my sleep schedule?

Official reports have included nervous system effects, such as insomnia (difficulty falling or staying asleep) and, less commonly, drowsiness, among the observed adverse reactions. Any changes to a person’s sleep schedule while using the medicine should be discussed with a healthcare provider.


Q: Is it true that Coponent can cause liver problems?

Regulatory documents advise that the medicine should be used with caution in individuals who already have impaired liver function, as this can slow the drug's clearance from the body. Official safety summaries have reported rare cases of abnormal hepatic function associated with its use.


Q: What kind of foods or drinks should I be careful about while taking Coponent?

The official drug interaction map specifically notes Grapefruit Juice as a concern. This is because Grapefruit Juice contains strong CYP3A4 inhibitors, which can potentially increase the drug’s concentration in the bloodstream. No other common foods or drinks are typically contra-indicated in the same manner.


Q: Does Coponent interact with common over-the-counter pain relievers?

The regulatory drug interaction map does not list a specific major interaction with common over-the-counter (OTC) pain relievers. However, regulatory guidance suggests discussing all OTC medicines, vitamins, and supplements being used with a healthcare professional due to the general potential for interaction.


Q: Is Coponent meant to be taken long-term or short-term?

The intravenous solution of the medicine is designated for short-term treatment used in acute care settings for rapid blood pressure control. Conversely, the oral capsule formulations are typically used for chronic, divided daily dosing that requires titration over several days to maintain therapeutic control.


Q: Does Coponent have any risk of dependence or withdrawal?

The official regulatory documentation does not classify this drug as having a risk of dependence or withdrawal. However, a specific regulatory warning notes that the medicine is not a beta-blocker and therefore offers no protection against the dangers of abrupt beta-blocker withdrawal if a patient is simultaneously taking that class of medication.


Q: Are there any known interactions between Coponent and common herbal supplements?

Official regulatory sources suggest that individuals discuss all herbal products and supplements being taken with a healthcare professional. This recommendation is due to the potential for interactions with the drug's metabolism that may not be explicitly detailed in the official product information.


Q: I've heard Coponent is a new drug—what's the original date of approval?

Nicardipine, the active ingredient in Coponent, was first approved for medical use by the FDA in December 1988. Since that time, it has been used in various formulations and is now widely available as a generic product.


Q: What should I do if the side effects of Coponent feel worse than expected?

If any side effects are bothersome, persist, or feel worse than expected, this information should be immediately discussed with a healthcare provider. This ensures the professional can assess the severity of the symptoms and offer appropriate guidance.


Q: Can I take Coponent if I have a history of [specific common medical condition, e.g., high blood pressure]?

Official literature indicates that the use of this drug requires specific caution, close monitoring, or dose adjustment in patients with certain pre-existing conditions. These cautionary conditions include impaired hepatic or renal function, heart failure, and a recent acute cerebral infarction.


Q: How long does Coponent stay in your system after you stop taking it?

The terminal plasma half-life of the oral capsule averages 8.6 hours. Based on regulatory pharmacokinetic data, the majority of the absorbed drug is typically eliminated from the body within 48 hours following the last dose administered.


Q: What are the restrictions on driving or operating machinery while on Coponent?

Official reports state the drug can cause side effects such as dizziness or sleepiness. Regulatory guidance suggests that caution should be exercised, and individuals should ensure they know how the medicine affects their ability to perform tasks like driving or operating machinery.


Q: Why is it important to check the expiration date on Coponent?

Regulatory requirements mandate that all pharmaceutical products retain their labeled strength and purity until the marked expiration date. After this date, the quality, effectiveness, and consistency of the medication can no longer be guaranteed.


Q: Is there a generic version of Coponent available?

Yes, the active ingredient is nicardipine hydrochloride. This substance is approved by regulatory agencies and is widely available in generic formulations that meet the required regulatory standards for use.


Q: Why does the official literature discuss its use with caution in people with a history of seizures?

Official safety literature advises caution when used in patients with certain existing neurological conditions. Specifically, caution is advised for individuals with an acute cerebral infarction (stroke) or pre-existing elevated intracranial pressure.


Q: If I have allergies, should I be concerned about the inactive ingredients in Coponent?

Official labeling states that the medicine must not be used by individuals with a known hypersensitivity to the active drug or to any of the excipients (inactive ingredients) in the formulation. It is recommended that individuals with general allergies review the full list of ingredients with a healthcare professional.


Q: How often do people usually need checkups or blood tests while on Coponent?

Official prescribing information does not mandate a single schedule for all users. However, it requires close monitoring for patients with specific conditions, such as impaired renal or hepatic function. Frequent blood pressure and heart rate monitoring are also explicitly required during intravenous administration.


Q: Can Coponent cause weight changes?

Weight change is not listed as a common side effect of the drug. However, official safety literature suggests that individuals immediately report a big weight gain or swelling in the arms or legs (edema) to a healthcare provider, as this may be related to fluid retention.


Q: I read about a study on Coponent and [vague symptom]—what did the study actually conclude?

Studies have examined the medicine’s use in chronic pain conditions like neuropathic pain and post-herpetic neuralgia. The trials focused on patient-reported outcomes, such as pain scales and sleep quality. Official research findings were reported as mixed regarding efficacy in these non-approved conditions.


Q: What are the signs that Coponent is not working as intended?

The general purpose of the drug is to achieve a lowering of elevated blood pressure. Therefore, a primary sign that the drug may not be working as intended is the lack of the desired blood pressure reduction. In clinical studies related to angina, a lack of improvement in exercise tolerance was also noted.


Q: Does Coponent interact with multivitamins?

Official drug interaction information notes that co-administration with a multivitamin with minerals can potentially decrease the effects of nicardipine. This is an example of an interaction that should be discussed with a healthcare professional to ensure therapeutic consistency.


Q: Why does Coponent have specific instructions regarding taking it with or without food?

Studies have indicated that taking the oral capsule after a high-fat meal may result in lower plasma levels of the drug. This effect on drug absorption is the primary reason why timing relative to meals may be an important factor for maintaining consistent therapeutic drug levels.


Q: Can Coponent affect mood or cause emotional changes?

Rare adverse effects reported in official safety summaries have included changes in mood or emotional state. These changes may involve feelings such as nervousness, irritability, and discouragement.


Q: What does it mean if my doctor says Coponent is a 'first-line treatment'?

The classification of a medicine as a first-line treatment means that it is often the initial drug recommended or preferred for managing a specific condition. For example, the intravenous formulation is often cited as the preferred choice in the management of Hypertensive Emergency situations.


Q: Does Coponent affect blood sugar levels?

Research conducted in hypertensive patients with non-insulin-dependent diabetes has produced mixed findings regarding the drug's effect on glucose metabolism and hemoglobin A1c (HbA1c) levels. Official regulatory literature does not make a singular definitive claim regarding its impact on blood sugar.


Q: What does the drug's manufacturer say about its potential long-term safety profile?

While research includes long-term data collection for study participants for up to one year, the official safety profile emphasizes the need for close monitoring in all populations. Specific focus is placed on monitoring for events such as increased chest pain upon the initiation of therapy or during dose escalation of the medicine.

How should Coponent be stored and disposed of?

The storage and disposal of Coponent (nicardipine) must follow specific regulatory requirements to ensure product integrity and safety.

Required Storage Conditions

Coponent must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from light and stored away from excess heat and moisture.

Formulation Restriction Mandatory Rule
Oral Capsules Keep in the original container and tightly closed.
IV Solution Do not freeze.

Disposal and Safety

All formulations must be stored out of the sight and reach of children.

Expired or unused Coponent must not be thrown away in household trash or wastewater. Disposal must be carried out in accordance with local requirements for pharmaceutical waste, such as through a designated drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coponent found in:

A-Z Index: